DCM
CLDX icon

Driehaus Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Driehaus Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8M Buy
+989,442
New +$32M 0.21% 147
2022
Q2 		– Sell
-292,292
Closed -$9.96M – 373
2022
Q1 		$9.96M Sell
292,292
-223,197
-43% -$7.13M 0.12% 233
2021
Q4 		$19.9M Sell
515,489
-35,576
-6% -$1.55M 0.2% 150
2021
Q3 		$29.8M Sell
551,065
-34,246
-6% -$1.61M 0.35% 85
2021
Q2 		$19.6M Buy
585,311
+236,471
+68% +$6.49M 0.26% 132
2021
Q1 		$7.19M Sell
348,840
-44,375
-11% -$1.02M 0.11% 247
2020
Q4 		$6.89M Sell
393,215
-8,548
-2% -$154K 0.11% 215
2020
Q3 		$5.96M Buy
401,763
+281,763
+235% +$3.3M 0.12% 189
2020
Q2 		$1.56M Buy
+120,000
New +$532K 0.04% 269
2015
Q3 		– Sell
-852
Closed -$322K – 550
2015
Q2 		$322K Sell
852
-643
-43% -$255K 0.01% 485
2015
Q1 		$625K Buy
+1,495
New +$535K 0.02% 445
2014
Q1 		– Sell
-21,275
Closed -$7.73M – 515
2013
Q4 		$7.73M Sell
21,275
-298
-1% -$115K 0.28% 107
2013
Q3 		$11.5M Buy
+21,573
New +$7.4M 0.44% 58

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Driehaus Capital Management's CLDX Position: Q2 2026 in Review

Driehaus Capital Management opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 989,442 shares worth $36.8M. The stake represents 0.21% of the portfolio and ranks #147 among its holdings. This is a return to the name: Driehaus Capital Management previously reported a position in CLDX as recently as Q1 2022.

Driehaus Capital Management first reported a position in CLDX in Q3 2013 and has held it in 13 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Driehaus Capital Management held 989,442 shares of Celldex Therapeutics worth $36.8M as of Q2 2026.
  • Celldex Therapeutics was a new Driehaus Capital Management position in Q2 2026.
  • Celldex Therapeutics made up 0.21% of Driehaus Capital Management's portfolio in Q2 2026, its #147 holding.
  • Driehaus Capital Management first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 13 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.